PT  - JOURNAL ARTICLE
AU  - Liu, Qing-Feng
AU  - Zhang, Zhi-Fei
AU  - Hou, Guang-Jie
AU  - Yang, Guang-Yu
AU  - He, Yi
TI  - Polymorphisms of the stem cell marker gene <em>CD133</em> are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients
AID  - 10.1136/bmjopen-2017-016913
DP  - 2017 Aug 01
TA  - BMJ Open
PG  - e016913
VI  - 7
IP  - 8
4099  - http://bmjopen.bmj.com/content/7/8/e016913.short
4100  - http://bmjopen.bmj.com/content/7/8/e016913.full
SO  - BMJ Open2017 Aug 01; 7
AB  - Objectives To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 (rs2240688A>C, rs10022537T>A, rs7686732C>G, and rs3130C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients.Design Retrospective cohort study.Setting Department of General Surgery, in a general hospital, Henan Province, China.Participants NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study.Outcome measures The primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up.Results There was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with thers2240688 AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations between CD133 rs2240688 polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33).Conclusions The study confirmed the significant association between the SNP rs2240688 A>C of CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of CD133 in NSCLC.